ESMO 2024 special: Results of interim analysis of SunRISe-4

UROONCO BCa chief editor Dr. Benjamin Pradere talks to Assoc. Prof. Andrea Necchi (IT) at EMSO 2024 on the results of the interim analysis of SunRISe-4 study: TAR-200 plus cetrelimab or CET alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy. Assoc. Prof. Necchi shares details of the study rationale and design, followed by an analysis of the results, and how these data could positively impact the future of treatment options for patients. According to Assoc. Prof. Necchi, the SunRISe-4 study results show for the first time that an intravesical treatment with TAR-200, combined with a systemic PD-1 inhibitor, could potentially result in a complete pathological response in a high proportion of patients.